highly significantP<0.01
Analysis of survival up to a maximum of 32 months in the first 150 patients entered shows highly significant survival advantage to 103 limited stage vs. 47 extensive stage patients (P<0.01, log rank test).
Analysis of survival up to a maximum of 32 months in the first 150 patients entered shows highly significant survival advantage to 103 limited stage vs. 47 extensive stage patients (P<0.01, log rank test).
Interestingly, there was a clear trend towards preferential retention in liver and tumour compared to brain, possibly reflecting the degree of nitroreductive bioactivation.